Spyre Therapeutics, Inc.
SYRE
$14.45
$0.322.27%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 1.16% | -7.50% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 10.58% | 25.47% | |||
| Operating Income | -10.58% | -25.47% | |||
| Income Before Tax | 18.42% | -77.69% | |||
| Income Tax Expenses | -94.44% | -- | |||
| Earnings from Continuing Operations | 18.44% | -77.74% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 18.44% | -77.74% | |||
| EBIT | -10.58% | -25.47% | |||
| EBITDA | -10.62% | -25.58% | |||
| EPS Basic | 102.89% | -58.27% | |||
| Normalized Basic EPS | 24.87% | -58.23% | |||
| EPS Diluted | 102.89% | -58.27% | |||
| Normalized Diluted EPS | 24.87% | -58.23% | |||
| Average Basic Shares Outstanding | 8.59% | 12.30% | |||
| Average Diluted Shares Outstanding | 8.59% | 12.30% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||